Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...

Teva Pharmaceutical is facing down plenty of lawsuits. Now, one of its chief rivals in the generics field is adding another case to Teva's plate. Mylan, which has merged with Pfizer's Upjohn to form ...

Sen. Patty Murray (D-WA) on Tuesday sent a letter to Mylan CEO Heather Bresch seeking more details, including e-mail communications, on the ways that Mylan attempted to keep Teva’s generic EpiPen from ...

Mylan Pharmaceutical may be getting some competition for its EpiPen, as Israel-based Teva Pharmaceutical Industries announced Friday that it hopes to launch its own generic version of the device by ...

Mylan has rejected Teva’s unsolicited bid. Robert J. Coury, Mylan’s executive chairman, said Teva’s roughly $40 billion offer grossly undervalues the company and “would require Mylan’s shareholders to ...

(Reuters) - Mylan NV's long-awaited U.S. approval for its generic version of rival Teva's blockbuster multiple sclerosis treatment Copaxone drove Mylan's shares up around 18 percent on Wednesday while ...